Researchers observed responses in patients with synovial sarcoma or myxoid/round cell liposarcoma treated with lete-cel.
GlobalData on MSN17d
Adaptimmune nears second sarcoma approval as Phase II trial hits endpointsAdaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback